• Dabigatran: Evidence, Research Context, and Limits

  2026-10-06

  Dabigatran, marketed as Pradaxa, is a direct thrombin inhibitor studied across atrial fibrillation, venous thromboembolism, and coagulation research. This overview compares published findings, explains how laboratory and clinical evidence relate, and outlines important limitations in applicability, safety interpretation, and evidence provenance.

• GlycoRNA–RBP Domains and TAT Cell Entry

  2026-10-06

  A 2023 bioRxiv preprint reports that cell-surface RNA-binding proteins and glycoRNAs assemble into nanoclusters that influence entry of the cell-penetrating peptide TAT. Its main contribution is a broader model of the plasma membrane in which extracellular RNA–protein organization, rather than transmembrane proteins alone, helps regulate cell–environment interactions.

• Bestatin (Ubenimex): A Mechanistic Evidence Map

  2026-10-05

  Bestatin (Ubenimex) is more than a generic protease inhibitor: its value lies in how its activity profile can be interpreted across M1 aminopeptidases, cellular phenotypes, and structural studies. This evidence-led guide explains what the data support, where uncertainty remains, and how Bestatin can inform cancer and multidrug resistance research without overstating translational relevance.

• ML365, NLRP3, and Postoperative Cognition

  2026-10-05

  A 2024 Brain Research study links ML365 pretreatment with improved postoperative cognitive performance in aged mice and reduced hippocampal NLRP3 inflammasome signaling. The work is innovative as a pharmacological bridge between two-pore potassium-channel biology and postoperative neuroinflammation, but it does not by itself establish direct TASK1 target engagement or clinical efficacy.

• Mild UPRER Activation and Cadmium Resistance in C. elegans

  2026-10-04

  A 2025 study in Caenorhabditis elegans shows that mild activation of the endoplasmic reticulum unfolded protein response can improve cadmium resistance by preserving protein homeostasis. The work identifies the IRE-1/XBP-1 branch as necessary for this protection while showing that excessive UPRER activation can be detrimental, defining an important boundary for interpreting ER-stress biology.

• Nanoparticle RNAi Delivery in Bemisia tabaci

  2026-10-03

  A 2026 study reports that C60/alkylpolyglucoside nanocarriers improved dsRNA-mediated silencing of btCHS and btG6PI in Bemisia tabaci compared with dsRNA alone. The findings support nanocarrier-assisted RNAi as a promising research direction, while remaining limited to a controlled tobacco–whitefly model and requiring further validation for field performance, specificity, and environmental safety.

• HyperScript™ Reverse Transcriptase and Adaptive Biology

  2026-10-01

  Transcriptional adaptation is only as credible as the RNA-to-cDNA workflow behind it. This thought-leadership article connects IP3R-deficient cell biology with strategic reverse-transcription decisions, showing how HyperScript™ Reverse Transcriptase can support structured, scarce, and long RNA targets while clarifying the limits of current evidence.

• Itraconazole for Candida Biofilm Research

  2026-10-01

  Itraconazole enables controlled studies of antifungal response, biofilm resistance, CYP3A4-mediated drug interactions, and pathway-linked phenotypes. This workflow connects the compound’s established handling characteristics with the PP2A–autophagy findings reported in Candida albicans biofilms.

• NF 449: Precision P2X1 Platelet Workflows

  2026-09-30

  NF 449 combines subnanomolar P2X1 potency with a practical workflow for separating ATP-driven platelet signaling from broader purinergic responses. This guide translates receptor profiling into aggregation, calcium-flux, and thrombosis-oriented experiments while emphasizing controls, concentration selection, and troubleshooting.

• Tianhuang Formula, Berberine, and RAGE/POMC Signaling

  2026-09-30

  A 2026 pre-proof study identifies RAGE as a leading central nervous system target of berberine within Tianhuang Formula and connects RAGE/POMC signaling with hypothalamic neuronal apoptosis, autophagy, and glucolipid regulation. Its integrated computational, cellular, and mouse-model design provides a mechanistic framework for metabolic disease research, while target specificity and clinical translation remain unresolved.

• Itraconazole: Triazole Antifungal Research Guide

  2026-09-29

  Itraconazole is a triazole antifungal agent with activity against Candida species and utility in CYP3A4-focused antifungal drug interaction studies. Its research value also includes investigation of Candida biofilm resistance, hedgehog signaling, and angiogenesis inhibition.

• Coumestrol: From ER Antagonism to Ferroptosis

  2026-09-29

  Coumestrol is more than a phytoestrogen estrogen receptor antagonist: it is a mechanistically informative research compound linking estrogen receptor signaling pathway biology with mitochondrial stress and ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. This thought-leadership analysis translates the evidence into practical assay strategy while defining the limitations that matter for translational interpretation.

• Ozone, Efferocytosis, and Neuropathic Pain

  2026-09-28

  Ruan et al. show that ozone reduces neuropathic pain in a chronic constriction injury model by enhancing macrophage efferocytosis through the AMPK/Gas6-MerTK/SOCS3 axis. The study links apoptotic-cell clearance to suppression of neuroinflammation and provides a mechanistic framework for evaluating efferocytosis as a therapeutic target.

• Rosiglitazone for PPARG Variant Assays

  2026-09-28

  Use Rosiglitazone to test whether a PPARG variant retains ligand-responsive activity—not just whether it changes adipocyte markers. A recent R212W study pairs receptor transcription with protein stability, mitochondrial function, and metabolic gene readouts, offering a practical blueprint for stronger type II diabetes research.

• Caspofungin Workflows for Candida Research

  2026-09-27

  Use Caspofungin to probe fungal cell-wall synthesis, benchmark antifungal susceptibility, and compare responses across Candida isolates. A practical workflow connects controlled in vitro testing with the delayed-treatment C. auris study—without confusing research findings with clinical recommendations.

8753 records 1/584 page Next 12345 下5页 Last page